<?xml version="1.0" encoding="UTF-8"?>
<fn-group>
 <fn id="fn2-1040797">
  <p>Check the online version for the most updated information on this article, online supplements, and information on authorship &amp; disclosures: 
   <ext-link ext-link-type="uri" xlink:href="www.haematologica.org/content/104/4/797" xmlns:xlink="http://www.w3.org/1999/xlink">www.haematologica.org/content/104/4/797</ext-link>
  </p>
 </fn>
 <fn id="fn3-1040797">
  <p>
   <bold>Funding</bold>
  </p>
  <p>This study was a collaboration within the Swedish CLL group and was supported by grants from AFA Insurance (Ref no: 130054), SLL/ALF (Ref no: 20150070), Blodcancerfonden 2016, Dr Åke Olsson Foundation (Ref no: 2-791/2016), SLL/KI Högre klinisk forskare 2018/2019 (K2894-2016), Svenska Läkaresällskapet (SLS-406961), The Gilead Sciences Nordic Fellowship Programme 2015 (LH), The Swedish Cancer Society (Ref no: 150930, 160534). We thank Ms Leila Relander for editorial assistance.</p>
 </fn>
</fn-group>
